HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer.

Abstract
Adipocytes are the primary cellular components within the tumor microenvironment (TME) of triple-negative breast cancer (TNBC). Increasing evidence suggests that tumor-associated adipocytes (TAAs) can aggravate tumor progression, exacerbate the immunosuppressive TME and compromise therapeutic efficacy. In this study, the biological effect of TAAs within the breast cancer TME is first investigated, and the C-C Motif Chemokine Ligand 2 (CCL2) which is mainly secreted by TAAs in the extracellular environment is identified as the key mediator. CCL2 recruits immune cells such as monocytes and macrophages that further differentiated into immunosuppressive myeloid-derived suppressor cells (MDSCs) and M2 macrophages. To manipulate CCL2-mediated immune response, a protein trap that binds with CCL2 with high affinity and specificity is designed. The plasmid DNA encoding the CCL2 trap (pCCL2) is specifically delivered to the TME by using targeted lipid-protamine-DNA (LPD) nanoparticles to locally express the CCL2 trap and ameliorate the immunosuppressive TME. Significantly, compared with the commercially available CCL2 antibody, this strategy shows enhanced therapeutic efficacy and appreciable tumor growth inhibition. Furthermore, the pCCL2 trap treatment successfully suppresses TAAs, increases T cell infiltration and decreases the population of immunosuppressive M2 macrophages and MDSCs. Further studies show that the pCCL2 trap could facilitate PD-L1 blockade immunotherapy, demonstrating its translation potential.
AuthorsYun Liu, Karthik Tiruthani, Menglin Wang, Xuefei Zhou, Nasha Qiu, Yang Xiong, Chad V Pecot, Rihe Liu, Leaf Huang
JournalNanoscale horizons (Nanoscale Horiz) Vol. 6 Issue 4 Pg. 319-329 (04 01 2021) ISSN: 2055-6764 [Electronic] England
PMID33587080 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Ccl2 protein, mouse
  • Chemokine CCL2
  • Drug Carriers
  • Lipids
  • Single-Domain Antibodies
  • DNA
Topics
  • Adipocytes (metabolism)
  • Animals
  • Cell Line, Tumor
  • Chemokine CCL2 (immunology, metabolism)
  • DNA (genetics)
  • Drug Carriers (chemistry)
  • Female
  • Genetic Therapy
  • Immunotherapy
  • Lipids (chemistry)
  • Mice, Inbred BALB C
  • Nanoparticles (chemistry)
  • Plasmids
  • Single-Domain Antibodies (genetics, immunology, therapeutic use)
  • Triple Negative Breast Neoplasms (therapy)
  • Tumor Microenvironment (immunology)
  • Mice

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: